Company: RDPTF
Filing Date: 2025-09-18
Form Type: 20-F
Source: 0001213900-25-088699
Chunk: 41

Company: Radiopharm Theranostics Ltd
Filing Date: 2025-09-18
Form: 20-F
Item: Item 3
Chunk 41
---
 performance-based consideration linked to the achievement of certain value-inflection development milestones and commercial
outcomes, as well as net sales-based royalty payments and sublicensing fees.

In September 2021, we entered
into an exclusive license agreement with Diaprost AB (“ Diaprost”) and Fredax AB (“ Fredax”). Under the terms of
the agreement, we have the exclusive rights to the technology Diaprost developed.

In August 2021, we entered
into a license agreement for the F-FPIA Imaging Agent with Cancer Research Technology Limited, a company incorporated in the UK. Under
the terms of the Agreement, we have the exclusive right to develop and commercialize the F-FPIA imaging Agent in the fields of diagnosis,
imaging, prevention and treatment of diseases.

In November 2021, we issued
20,000,000 convertible notes at A$1.00 per note to a number of sophisticated investors. The subscription amounts were intended to satisfy
upfront obligations under the current license agreements and to complete an initial public offer in Australia. The convertible notes were
converted upon completion of Radiopharm’s initial public offering in Australia in 2021.

In November 2021, our ordinary shares listed on
the ASX under the symbol “ RAD”.

In June 2022, we entered into
an exclusive sublicensing agreement with NeoIndicate, LLC (“ NeoIndicate”), a U. S. limited liability company, to a PTPµ-targeted
radiopharmaceutical agent, which was developed at Case Western Reserve University (“ CWRU”) in Ohio. The sublicensing agreement
grants us the rights to develop the PTPµ-targeted agent as an imaging diagnostic and as a targeted radiopharmaceutical theranostic
as part of our clinical development pipeline.

In July 2022, Radiopharm Ventures,
LLC, was formed in Delaware. Its primary purpose is to develop and commercialize diagnostic and therapeutic antibody-based products using
intellectual property licensed from The Board of Regents of The University of Texas System and The University of Texas M. D. Anderson Cancer
Center (collectively, “ M. D. Anderson”) pursuant to a Technology Commercialization Agreement entered into between MD Anderson
and Radiopharm Therapeutics (USA) Inc. (“ Radiopharm USA”) in September 2022. Our wholly-owned subsidiary Radiopharm USA owns
75% of the issued units of Radiopharm Ventures and MD Anderson owns 25%. Radiopharm